Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.

Vaccine - 25 Jan 2018

Malm Maria, Tamminen Kirsi, Heinimäki Suvi, Vesikari Timo, Blazevic Vesna

Abstract excerpt

Norovirus (NoV) is the main cause of acute gastroenteritis worldwide across all age groups. Current NoV vaccine candidates are based on non-infectious highly immunogenic virus-like particles (VLPs) produced in cell cultures in vitro. As NoVs infecting human population are highly divergent, it is proposed that the vaccine should contain at least two different NoV genotypes, potentially affecting the immunogenicity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antibody Specificity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Caliciviridae Infections

Share to Cell Degranulation

Share to Cross Reactions

Share to Norovirus

Share to T-Cell Antigen Receptor Specificity

Share to Viral Vaccines

Source

Identifiers

PMID: 29246474
DOI: 10.1016/j.vaccine.2017.12.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.PMID 29246474Read ↗

Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.Semantic proximity Read ↗

Integrated in-silico design and in vivo validation of multi-epitope vaccines for norovirusSemantic proximity Read ↗

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccineSemantic proximity Read ↗

Characterization of the homo- and heterotypic immune responses after natural norovirus infection.Semantic proximity Read ↗

Pre-existing immunity to norovirus GII-4 virus-like particles does not impair de novo immune responses to norovirus GII-12 genotype.Semantic proximity Read ↗

Characterization of high affinity IgM and IgG monoclonal antibodies against norovirus variants GII.4 and GII.17Semantic proximity Read ↗

Epidemiology of human noroviruses and updates on vaccine development.Semantic proximity Read ↗

Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune ResponsesSemantic proximity Read ↗

Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.Semantic proximity Read ↗

Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.Semantic proximity Read ↗

Norovirus-Specific Memory T Cell Responses in Adult Human DonorsSemantic proximity Read ↗

Production, characterization and immunogenicity of P particles derived from norovirus GII.4 genotype 2004 variant.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.